drugset
drugset / Trial / NCT04264936

A Study of RC48-ADC(Antibody Drug Conjugate) and JS001 to Evaluate the Safety and Pharmacokinetics of Subjects With Locally Advanced or Metastatic Urothelial Cancer

NCT04264936 ↗

Phase 1/2 Unknown 36 enrolled Peking University Cancer Hospital & Institute
NaSingle-groupOpen-labelTreatment

Summary

This is an open-label, single-arm, Phase Ib/II investigator-initiated trial of RC48-ADC combined with JS001 to evaluate the safety and pharmacokinetics of subjects with locally advanced or metastatic urothelial cancer

Timeline

Start
2020-02-15
Primary completion
2021-01-30
Completion
2021-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Disitamab Vedotin Monoclonal antibody — —
Subject Toripalimab Monoclonal antibody — —

Indications

urothelial carcinoma